KPN Sells Belgian Mobile Unit

Related Link: 

KPN is selling BASE to Telenet for $1.42 billion, allowing the Dutch telecom firm to focus on its integrated access strategy in the Netherlands.

Legacy Oil Forms Committee to Engage with Activist Shareholder

Related Link: 

Legacy Oil + Gas Inc. said Monday that its board has formed a special committee to engage with an activist investor seeking to shake up the Calgary-based company’s board.

L'Oréal Sales Bolstered by Weak Euro

Related Link: 

French cosmetics giant L’Oréal SA posted a strong rise in first-quarter sales, buoyed by a “very positive currency impact” following the recent slide in euro against the dollar.

Chevron, Donziger to Face Off

Related Link: 

Chevron will go head-to-head in an appeals court Monday with the lawyer who has tried for years to get the oil giant to pay a $9.5 billion environmental-damage award.

Comcast Strives to Save Merger

Related Link: 

Comcast and Time Warner Cable are set to meet with the Justice Department to discuss potential remedies in a bid to save their planned deal.

Cirque du Soleil Being Sold to Private-Equity Group

Related Link: 

Cirque du Soleil’s founder has agreed to sell his controlling stake in the Canadian circus company to an investor group led by U.S. private-equity firm TPG.

Oil Rigs' Biggest Risk: Human Error

Related Link: 

Five years after the Deepwater Horizon oil spill, government and industry officials continue to wrestle with a problem investigators say was at the heart of the disaster: human error.

Malakoff Adds Spark to Malaysia IPO Scene

Related Link: 

Investors are piling into the $754 million initial public offering of Malaysian power producer Malakoff.

Canada's Own Pipeline Problem

Related Link: 

The proposed Northern Gateway, part of a Canadian effort to boost oil exports to Asia, has hit opposition by native groups who say it threatens their environment and culture.

Bristol-Myers Drug Combination Shows Promise

Related Link: 

A combination of Bristol-Myers’s Opdivo and Yervoy was significantly more effective in stifling tumors in melanoma patients in a study than using just one of the treatments alone.

Syndicate content